EBITDA: Income before interest, taxes, depreciation and amortization.
Aspire Biopharma Holdings, Inc. (ASBP) had EBITDA of $-11.33M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$0.01M |
|
$-24.48M |
|
$0.01M |
|
$-0.00M |
|
$19.36M |
|
$-19.35M |
|
$-5.13M |
|
$-24.48M |
|
$-24.48M |
|
$-24.48M |
|
$-24.48M |
|
$-24.48M |
|
$-24.48M |
|
$-19.35M |
|
|
EBITDA |
$-11.33M |
1.50M |
|
1.50M |
|
$-16.38 |
|
$-16.38 |
|
| Balance Sheet Financials | |
$1.31M |
|
-- |
|
-- |
|
$1.31M |
|
$7.59M |
|
-- |
|
$0.10M |
|
$7.69M |
|
$-6.38M |
|
$-6.38M |
|
$-6.38M |
|
3.53M |
|
| Cash Flow Statement Financials | |
$-4.92M |
|
-- |
|
$5.92M |
|
$0.00M |
|
$1.00M |
|
$1.00M |
|
$14.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.17 |
|
-- |
|
-- |
|
-- |
|
-0.81 |
|
-1.87% |
|
-312016.90% |
|
-312016.90% |
|
-182712.70% |
|
-394725.10% |
|
-394725.10% |
|
$-4.92M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
0.03 |
|
-- |
|
-- |
|
383.93% |
|
383.93% |
|
-1865.68% |
|
383.93% |
|
$-1.80 |
|
$-3.29 |
|
$-3.29 |
|